New Targets in Non-Small Cell Lung Cancer

With the implementation of genomic technologies into clinical practice, patients have seen meaningful benefits with targeted therapy for oncogeneaddicted cancer, and we have identified new molecular dependencies in non-small cell lung cancer. The clinical success of tyrosine kinase inhibitors against epidermal growth factor receptor and anaplastic lymphoma kinase activation has shifted treatment options toward the separation of subsets of lung cancer and the administration of genotype-directed therapy. Drug development is underway for a host of new molecular targets. This review highlights treatment options, including clinical trials for ROS1 rearrangement, RET fusions, NTRK1 fusions, MET exon skipping, BRAF mutations, and KRAS mutations.